| Overview |
| bs-5804R |
| NAIP Polyclonal Antibody |
| WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human NAIP |
| 1151-1250/1403 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 4671 |
| Nucleus, Secreted, Cell membrane, Extracellular matrix |
| Baculoviral IAP repeat containing 1; Baculoviral IAP repeat-containing protein 1; BIRC 1; BIRC1; BIRC1_HUMAN; Birc1a; NAIP; Naip1; Neuronal apoptosis inhibitory protein; NLR family apoptosis inhibitory protein; NLR family BIR domain containing 1; NLRB 1; NLRB1; Nucleotide binding oligomerization domain leucine rich repeat and BIR domain containing 1; Psi neuronal apoptosis inhibitory protein; psiNAIP; Similar to occludin. |
| Prevents motor-neuron apoptosis induced by a variety of signals. Possible role in the prevention of spinal muscular atrophy that seems to be caused by inappropriate persistence of motor-neuron apoptosis: mutated or deleted forms of NAIP have been found in individuals with severe spinal muscular atrophy. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz